Insight Molecular Diagnostics (IMDX) said a new Medicare policy is favorable for expanded coverage of donor-derived cell-free DNA (dd-cfDNA) testing in transplant care. The update supports a potential increase in reimbursement/access for the company’s testing, though no financial figures or timeline were provided in the release.
Insight Molecular Diagnostics (IMDX) said a new Medicare policy is favorable for expanded coverage of donor-derived cell-free DNA (dd-cfDNA) testing in transplant care. The update supports a potential increase in reimbursement/access for the company’s testing, though no financial figures or timeline were provided in the release.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
